The largest challenge with the genetic aberrations of pancreatic cancer is that the KRAS oncogene has been ‘undruggable’ using the now conventional treatment approach of targeted chemical inhibitors [18]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.